Skip to content
Lifitegrast
Xiidra (lifitegrast) is a small molecule pharmaceutical. Lifitegrast was first approved as Xiidra on 2016-07-11. It is used to treat dry eye syndromes in the USA. The pharmaceutical is active against integrin alpha-L.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
Trade Name
FDA
EMA
Xiidra
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lifitegrast
Tradename
Company
Number
Date
Products
XIIDRANovartisN-208073 RX2016-07-11
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
xiidraNew Drug Application2020-07-31
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
dry eye syndromes—D015352H04.12
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Lifitegrast, Xiidra, Novartis
110586772033-12-18DP
90855532033-07-25DP
89275742030-11-12DP
93530882030-10-21DP
98901412030-10-21DP
81686552029-05-09U-1880
83677012029-04-15DPU-1880
94470772029-04-15U-1900
80840472026-05-17DS, DP
85924502026-05-17U-1880
73149382025-03-10DS, DP
77454602024-11-05DS, DPU-1880
77907432024-11-05U-1880
79281222024-11-05DS, DP
92161742024-11-05DP
101240002024-11-05U-1900
ATC Codes
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01X: Other ophthalmologicals in atc
— S01XA: Other ophthalmologicals in atc
— S01XA25: Lifitegrast
HCPCS
No data
Clinical
Clinical Trials
2 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OnychomycosisD014009B35.11————1
Wounds and injuriesD014947T14.81————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLIFITEGRAST
INNlifitegrast
Description
Lifitegrast is an N-acyl-L-alpha-amino acid obtained by formal condensation of the carboxy group of N-[2-(1-benzofuran-6-carbonyl)]-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid with the amino group of 3-(methanesulfonyl)-L-phenylalanine. Used for treatment of keratoconjunctivitis sicca (dry eye syndrome). It has a role as an anti-inflammatory drug and a lymphocyte function-associated antigen-1 antagonist. It is a L-phenylalanine derivative, a sulfone, a N-acyl-L-alpha-amino acid, a member of isoquinolines and a member of 1-benzofurans.
Classification
Small molecule
Drug classantiasthmatics/antiallergics (not acting primarily as antihistamines): integrin antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3c(c2Cl)CCN(C(=O)c2ccc4ccoc4c2)C3)C(=O)O)c1
Identifiers
PDB—
CAS-ID1025967-78-5
RxCUI1801820
ChEMBL IDCHEMBL2048028
ChEBI ID—
PubChem CID11965427
DrugBankDB11611
UNII ID038E5L962W (ChemIDplus, GSRS)
Target
Agency Approved
ITGAL
ITGAL
Organism
Homo sapiens
Gene name
ITGAL
Gene synonyms
CD11A
NCBI Gene ID
3683
Protein name
integrin alpha-L
Protein synonyms
antigen CD11A (p180), lymphocyte function-associated antigen 1, alpha polypeptide, CD11 antigen-like family member A, CD11a, integrin gene promoter, integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide), Leukocyte adhesion glycoprotein LFA-1 alpha chain, Leukocyte function-associated molecule 1 alpha chain, LFA-1 alpha, LFA-1A, lymphocyte function-associated antigen 1, alpha polypeptide
Uniprot ID
P20701
Mouse ortholog
Itgal (16408)
integrin alpha-L (Q3U159)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Xiidra - Novartis
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 537 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3 adverse events reported
View more details